Sanofi buys rights to Principia’s BTK inhibitor by Selina McKee | Nov 10, 2017 | News | 0 Sanofi has bought itself rights to Principia BioPharma’s experimental tyrosine kinase (BTK) inhibitor PRN2246, in a deal potentially worth more than $800 million to the latter firm. Read More